Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $6.6 million.

  • China Pharma Holdings' Total Current Liabilities rose 3912.85% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 3912.85%. This contributed to the annual value of $5.0 million for FY2024, which is 2643.99% down from last year.
  • As of Q3 2025, China Pharma Holdings' Total Current Liabilities stood at $6.6 million, which was up 3912.85% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Total Current Liabilities ranged from a high of $12.7 million in Q4 2022 and a low of $4.7 million during Q2 2024
  • Over the past 5 years, China Pharma Holdings' median Total Current Liabilities value was $8.4 million (recorded in 2022), while the average stood at $8.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 5532.22% in 2024, then skyrocketed by 3912.85% in 2025.
  • Over the past 5 years, China Pharma Holdings' Total Current Liabilities (Quarter) stood at $10.5 million in 2021, then increased by 21.17% to $12.7 million in 2022, then crashed by 46.46% to $6.8 million in 2023, then decreased by 26.44% to $5.0 million in 2024, then surged by 32.0% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $5.3 million for Q2 2025, and $5.1 million during Q1 2025.